These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 14683472)
1. Selective protein kinase C inhibitors and their applications. Shen GX Curr Drug Targets Cardiovasc Haematol Disord; 2003 Dec; 3(4):301-7. PubMed ID: 14683472 [TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism. Chen CC; Wang JK; Lin SB J Immunol; 1998 Dec; 161(11):6206-14. PubMed ID: 9834107 [TBL] [Abstract][Full Text] [Related]
3. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Koya D; Jirousek MR; Lin YW; Ishii H; Kuboki K; King GL J Clin Invest; 1997 Jul; 100(1):115-26. PubMed ID: 9202063 [TBL] [Abstract][Full Text] [Related]
4. The role of protein kinase C activation and the vascular complications of diabetes. Das Evcimen N; King GL Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431 [TBL] [Abstract][Full Text] [Related]
5. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Carter CA Curr Drug Targets; 2000 Sep; 1(2):163-83. PubMed ID: 11465069 [TBL] [Abstract][Full Text] [Related]
6. Protein kinase C isozymes as potential targets for anticancer therapy. Hofmann J Curr Cancer Drug Targets; 2004 Mar; 4(2):125-46. PubMed ID: 15032665 [TBL] [Abstract][Full Text] [Related]
7. The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta. Wellner M; Maasch C; Kupprion C; Lindschau C; Luft FC; Haller H Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):178-85. PubMed ID: 9888881 [TBL] [Abstract][Full Text] [Related]
8. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. Jirousek MR; Gillig JR; Gonzalez CM; Heath WF; McDonald JH; Neel DA; Rito CJ; Singh U; Stramm LE; Melikian-Badalian A; Baevsky M; Ballas LM; Hall SE; Winneroski LL; Faul MM J Med Chem; 1996 Jul; 39(14):2664-71. PubMed ID: 8709095 [TBL] [Abstract][Full Text] [Related]
9. Protein kinase C and the development of diabetic vascular complications. Way KJ; Katai N; King GL Diabet Med; 2001 Dec; 18(12):945-59. PubMed ID: 11903393 [TBL] [Abstract][Full Text] [Related]
10. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Frank RN Am J Ophthalmol; 2002 May; 133(5):693-8. PubMed ID: 11992868 [TBL] [Abstract][Full Text] [Related]
11. The epsilon isoform of protein kinase C is involved in regulation of the LTD(4)-induced calcium signal in human intestinal epithelial cells. Thodeti CK; Nielsen CK; Paruchuri S; Larsson C; Sjölander A Exp Cell Res; 2001 Jan; 262(2):95-103. PubMed ID: 11139333 [TBL] [Abstract][Full Text] [Related]
12. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and -delta. Bennasser Y; Bahraoui E FASEB J; 2002 Apr; 16(6):546-54. PubMed ID: 11919157 [TBL] [Abstract][Full Text] [Related]
14. Protein kinase C activation and its pharmacological inhibition in vascular disease. Meier M; King GL Vasc Med; 2000; 5(3):173-85. PubMed ID: 11104300 [TBL] [Abstract][Full Text] [Related]
16. PKC-B inhibition: a new therapeutic approach for diabetic complications? Avignon A; Sultan A Diabetes Metab; 2006 Jun; 32(3):205-13. PubMed ID: 16799396 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Aiello LP; Bursell SE; Clermont A; Duh E; Ishii H; Takagi C; Mori F; Ciulla TA; Ways K; Jirousek M; Smith LE; King GL Diabetes; 1997 Sep; 46(9):1473-80. PubMed ID: 9287049 [TBL] [Abstract][Full Text] [Related]
18. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Idris I; Gray S; Donnelly R Diabetologia; 2001 Jun; 44(6):659-73. PubMed ID: 11440359 [TBL] [Abstract][Full Text] [Related]
19. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Bosco R; Melloni E; Celeghini C; Rimondi E; Vaccarezza M; Zauli G Mini Rev Med Chem; 2011 Mar; 11(3):185-99. PubMed ID: 21534929 [TBL] [Abstract][Full Text] [Related]
20. Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene. Li H; Oehrlein SA; Wallerath T; Ihrig-Biedert I; Wohlfart P; Ulshöfer T; Jessen T; Herget T; Förstermann U; Kleinert H Mol Pharmacol; 1998 Apr; 53(4):630-7. PubMed ID: 9547352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]